+

WO2008156069A1 - Procédé de criblage pour un anticorps et anticorps obtenu par le procédé - Google Patents

Procédé de criblage pour un anticorps et anticorps obtenu par le procédé Download PDF

Info

Publication number
WO2008156069A1
WO2008156069A1 PCT/JP2008/061017 JP2008061017W WO2008156069A1 WO 2008156069 A1 WO2008156069 A1 WO 2008156069A1 JP 2008061017 W JP2008061017 W JP 2008061017W WO 2008156069 A1 WO2008156069 A1 WO 2008156069A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
production
screening method
specific surface
Prior art date
Application number
PCT/JP2008/061017
Other languages
English (en)
Japanese (ja)
Inventor
Tadao Okamoto
Masami Miura
David King
Asna Masood
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of WO2008156069A1 publication Critical patent/WO2008156069A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

La présente invention a pour objet un nouveau procédé de criblage pour un anticorps, un anticorps obtenu par le procédé et une composition pharmaceutique renfermant l'anticorps en tant que principe actif. Le procédé de criblage pour un anticorps dirigé contre un antigène de surface spécifique des lymphocytes B, comprend les étapes consistant à : i) ajouter un anticorps dirigé contre un antigène de surface des lymphocytes B à des lymphocytes B ; ii) confirmer que la production d'IL-6 par les lymphocytes B est modifiée et/ou confirmer que la production d'IL-10 par les lymphocytes B est modifiée. L'anticorps est dirigé contre un antigène de surface spécifique des lymphocytes B et possède une action de modification de la production d'IL-6 par les lymphocytes B et/ou possède une action de modification de la production d'IL-10 par les lymphocytes B. La composition pharmaceutique contient l'anticorps en tant que principe actif.
PCT/JP2008/061017 2007-06-18 2008-06-17 Procédé de criblage pour un anticorps et anticorps obtenu par le procédé WO2008156069A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007160531A JP2010222255A (ja) 2007-06-18 2007-06-18 抗体のスクリーニング方法およびそれにより得られる抗体
JP2007-160531 2007-06-18

Publications (1)

Publication Number Publication Date
WO2008156069A1 true WO2008156069A1 (fr) 2008-12-24

Family

ID=40156228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061017 WO2008156069A1 (fr) 2007-06-18 2008-06-17 Procédé de criblage pour un anticorps et anticorps obtenu par le procédé

Country Status (3)

Country Link
JP (1) JP2010222255A (fr)
TW (1) TW200920399A (fr)
WO (1) WO2008156069A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239181A (zh) * 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 用于鉴定细胞表面抗原的免疫结合剂的方法
EP3774919A4 (fr) * 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructions ciblant cd22 et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526501A (ja) * 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526501A (ja) * 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CROSS J.T. ET AL.: "The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus", INFLAMM. RES., vol. 48, no. 5, 1999, pages 255 - 261, XP002506261 *
EDWARDS J.C. ET AL.: "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis", N. ENGL. J. MED., vol. 350, no. 25, 2004, pages 2572 - 2581, XP008067127 *
FILLATREAU S. ET AL.: "B cells regulate autoimmunity by provision of IL-10", NAT. IMMUNOL., vol. 3, no. 10, 2002, pages 944 - 950 *
OTSUKA J. ET AL.: "Jiko Men'eki Shikkan o Megutte SLE ni Okeru B-Saibo Kogen Juyotai Signal Dentatsu Ijo", CLINICAL IMMUNOLOGY, vol. 40, no. 1, 2003, pages 43 - 49 *
SATO S.: "Jiko Kotai no Sansei Kijo to Sono Byogensei Zenshinsei Kyohisho ni Okeru B-Saibo Ijo to Jiko Kotai Sansei", JAPANESE JOURNAL OF CLINICAL IMMUNOLOGY, vol. 29, no. 2, 2006, pages 73 - 84 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239181A (zh) * 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 用于鉴定细胞表面抗原的免疫结合剂的方法
US8465937B2 (en) 2009-02-24 2013-06-18 ESBATech, an Alcon Biomedical Research Unit, LLC Methods for identifying B-clones which bind cell-surface antigens
US9221905B2 (en) 2009-02-24 2015-12-29 Esbatech, An Alcon Biomedical Research Unit Llc Methods for producing immunobinders of cell-surface antigens
US9908940B2 (en) 2009-02-24 2018-03-06 Esbatech, An Alcon Biomedical Research Unit Llc Humanized immunobinders of cell-surface antigens
EP3774919A4 (fr) * 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructions ciblant cd22 et leurs utilisations

Also Published As

Publication number Publication date
TW200920399A (en) 2009-05-16
JP2010222255A (ja) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2010031720A3 (fr) Nouvelle formulation d’anticorps
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
WO2007035545A3 (fr) Appareil, procede et systeme destines a construire des logiciels par la composition
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
WO2007093627A3 (fr) Composition biocide
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
WO2007117490A3 (fr) Purification d'anticorps
WO2012156998A3 (fr) Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron
WO2008066558A3 (fr) Procédé pour la préparation de 2-5-(1-alkylthio)alkylpyridines substitués
WO2010049454A3 (fr) Composition antimicrobienne tirée de copépodes
WO2008083950A3 (fr) Dérivés spirocycliques de l'acide tétronique
WO2011131368A3 (fr) Procédé de préparation d'une forme galénique orale comprenant du fingolimod
WO2010102778A3 (fr) 3-aminoisoxazolopyridines substituées en tant que modulateurs de kcnq 2/3
WO2012131707A3 (fr) Nouvelle forme cristalline de bortezomib, son procédé de préparation et composition pharmaceutique l'utilisant
WO2009053446A3 (fr) Nouveaux intermédiaires de prégabaline et procédé de préparation desdits intermédiaires et de prégabaline
WO2012017322A3 (fr) Composition pharmaceutique et procédé d'inhibition de la production ou d'amplification de l'élimination de la protéine p24
WO2008116056A3 (fr) Nouveaux procédés de production de 5-épi-β-vétivone, de 2-isopropyl-6,10-diméthyl-spiro[4.5]déca-2,6-dién-8-one et de 2-isopropyl-6,10-diméthyl-spiro[4.5]déca-1,6-dién-8-one
WO2008073863A3 (fr) Préparation et utilité d'allylamines substituées
WO2011129562A3 (fr) Procédé de production à grande échelle de nanoparticules d'argent ayant une dimension uniforme
WO2010015656A3 (fr) Nouveaux alcoxypyrazoles
WO2012148148A3 (fr) Nouveau complexe d'azide de zinc et procédé de préparation de dérivés de tétrazole l'utilisant
WO2009062659A3 (fr) Polymorphes d'erdostéine énantiopure
WO2008094617A3 (fr) Formes cristallines de déférasirox
WO2007013043A3 (fr) Procedes d'elaboration d'acide 7-amino-3-vinyl cephalosporanique
WO2008156069A1 (fr) Procédé de criblage pour un anticorps et anticorps obtenu par le procédé

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777255

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777255

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载